ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Flagship Pioneering, Inc.
This role involves building the physics layer of a drug development AI platform by characterizing binder-target engagements and validating generated designs prior to synthesis. The position requires expertise in molecular simulations, free energy predictions, and converting simulation outputs into training signals for generative machine learning models. The successful candidate will work cross-functionally to develop automated simulation pipelines and support drug discovery efforts through advanced computational methods.
Headquarters
Cambridge, Massachusetts, United States
Company Size
201-500 employees
Founded
2000
Flagship Pioneering is a venture creation and investment firm that invents, builds, and funds early-stage companies in biotechnology, life sciences, and sustainability. Using an integrated model of in-house science, lab infrastructure, capital, and operational support, it spins out and scales breakthrough ventures — it has helped found more than 100 companies, including high-profile names such as Moderna. Flagship focuses on deep‑science innovation and long‑term partnerships to translate novel discoveries into transformative products for human health and the planet.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Flagship Pioneering, Inc..
39% above the average for this role
individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week
Jul 20, 2025
Computational Biophysics Scientist
Lila Sciences
ML & Molecular Simulation Scientist
Genesis Molecular AI
Post-doctoral Computational Chemist, Advanced Molecular Design
Eli Lilly and Company
Post-Doctoral Fellow
The Wistar Institute
Molecular Simulations Specialist-Senior Scientist
AstraZeneca
Senior Computational Chemist, Drug Discovery (UK)
SandboxAQ
